Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Creating Preventive Vaccines for Lynch Syndrome

JAMA Oncology; ePub 2018 Apr 16; Chang, et al

Understanding the immune profile associated with the premalignant lesions of Lynch syndrome may open the door to the development of preventive vaccines for the disorder, according to a whole genome transcriptomic analysis of colorectal polyps and carcinomas in patients with Lynch syndrome.

  • The genetic analysis was performed on 28 polyps and 3 early stage Lynch syndrome colorectal tumors in 24 patients with Lynch syndrome and familial adenomatous polyposis.
  • Lynch syndrome polyps had a unique immune activation profile that included CD4 T cells, tumor necrosis factor and interleukin 12 molecules, as well as checkpoint molecules, including lymphocyte activation gene 3 and programmed cell death 1 ligand 1.
  • The findings suggest that immune checkpoint inhibitors and preventive vaccines may help combat Lynch syndrome.

Citation:

Chang K, Taggart MW, Reyes-Uribe L, et al. Immune profiling of premalignant lesions in patients with Lynch syndrome. [Published online ahead of print April 16, 2018]. JAMA Oncol. doi:10.1001/jamaoncol.2018.1482.